| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 35 | 2023 | 1076 | 6.220 |
Why?
|
| Head and Neck Neoplasms | 39 | 2024 | 1052 | 5.630 |
Why?
|
| Oropharyngeal Neoplasms | 15 | 2023 | 118 | 4.090 |
Why?
|
| Mouth Neoplasms | 12 | 2023 | 194 | 3.530 |
Why?
|
| Papillomavirus Infections | 16 | 2023 | 239 | 3.350 |
Why?
|
| DNA, Neoplasm | 10 | 2020 | 265 | 2.410 |
Why?
|
| Thyroid Neoplasms | 12 | 2024 | 408 | 2.380 |
Why?
|
| Mutation | 27 | 2024 | 3968 | 1.500 |
Why?
|
| Carcinoma | 8 | 2022 | 436 | 1.380 |
Why?
|
| Receptor, Notch1 | 9 | 2020 | 85 | 1.330 |
Why?
|
| Papillomaviridae | 9 | 2022 | 153 | 1.280 |
Why?
|
| Laryngectomy | 8 | 2017 | 26 | 1.160 |
Why?
|
| Biomarkers, Tumor | 12 | 2022 | 1464 | 1.150 |
Why?
|
| Neck Dissection | 5 | 2017 | 65 | 1.110 |
Why?
|
| Tongue Neoplasms | 6 | 2018 | 50 | 1.040 |
Why?
|
| Exome | 5 | 2017 | 127 | 1.030 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2020 | 381 | 0.970 |
Why?
|
| Humans | 121 | 2024 | 86643 | 0.970 |
Why?
|
| Tonsillar Neoplasms | 3 | 2019 | 6 | 0.950 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 252 | 0.930 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 316 | 0.890 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 301 | 0.890 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 57 | 0.880 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 89 | 0.880 |
Why?
|
| Alphapapillomavirus | 4 | 2021 | 45 | 0.860 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2022 | 66 | 0.860 |
Why?
|
| Saliva | 3 | 2021 | 122 | 0.860 |
Why?
|
| Middle Aged | 54 | 2024 | 25028 | 0.790 |
Why?
|
| Betacoronavirus | 3 | 2020 | 258 | 0.770 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2022 | 28 | 0.760 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 1313 | 0.750 |
Why?
|
| Male | 66 | 2023 | 40965 | 0.750 |
Why?
|
| Pandemics | 4 | 2020 | 740 | 0.750 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 158 | 0.750 |
Why?
|
| Tracheotomy | 1 | 2020 | 18 | 0.740 |
Why?
|
| Neoplasm Staging | 14 | 2022 | 1939 | 0.740 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 30 | 0.710 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 552 | 0.700 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 154 | 0.700 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 47 | 0.660 |
Why?
|
| Female | 64 | 2024 | 44532 | 0.650 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 150 | 0.650 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.650 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.640 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.640 |
Why?
|
| Thyroidectomy | 7 | 2022 | 170 | 0.620 |
Why?
|
| Prognosis | 17 | 2022 | 3679 | 0.610 |
Why?
|
| Life Style | 1 | 2018 | 189 | 0.590 |
Why?
|
| Liquid Biopsy | 4 | 2023 | 33 | 0.580 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 7 | 0.560 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.560 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 128 | 0.560 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 265 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1036 | 0.540 |
Why?
|
| Disability Evaluation | 1 | 2016 | 136 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 2271 | 0.530 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2014 | 157 | 0.530 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 329 | 0.510 |
Why?
|
| Neck | 4 | 2015 | 100 | 0.510 |
Why?
|
| Adult | 39 | 2023 | 25648 | 0.500 |
Why?
|
| Aged | 34 | 2020 | 18415 | 0.500 |
Why?
|
| Incidence | 7 | 2022 | 1577 | 0.500 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 1169 | 0.480 |
Why?
|
| Postoperative Complications | 8 | 2016 | 2207 | 0.470 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 388 | 0.460 |
Why?
|
| Retrospective Studies | 20 | 2022 | 8489 | 0.460 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2024 | 13 | 0.460 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 151 | 0.450 |
Why?
|
| Salvage Therapy | 3 | 2015 | 233 | 0.450 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 11 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2012 | 21 | 0.450 |
Why?
|
| Lymph Nodes | 5 | 2017 | 533 | 0.430 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2023 | 70 | 0.430 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 93 | 0.410 |
Why?
|
| F-Box Proteins | 1 | 2011 | 8 | 0.410 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 19 | 0.410 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2011 | 165 | 0.410 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2023 | 71 | 0.400 |
Why?
|
| Clostridium | 4 | 2005 | 21 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2023 | 2767 | 0.390 |
Why?
|
| Monitoring, Intraoperative | 4 | 2018 | 109 | 0.390 |
Why?
|
| Tonsillectomy | 3 | 2023 | 30 | 0.370 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2022 | 17 | 0.370 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 321 | 0.370 |
Why?
|
| United States | 11 | 2022 | 6672 | 0.360 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 173 | 0.350 |
Why?
|
| ras Proteins | 2 | 2020 | 128 | 0.340 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 456 | 0.330 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 6509 | 0.330 |
Why?
|
| Sex Factors | 5 | 2018 | 1054 | 0.320 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 53 | 0.320 |
Why?
|
| Parathyroid Hormone | 3 | 2018 | 218 | 0.310 |
Why?
|
| Age Factors | 5 | 2018 | 1851 | 0.310 |
Why?
|
| Pharyngectomy | 3 | 2016 | 8 | 0.300 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2018 | 41 | 0.300 |
Why?
|
| Neoplasms, Experimental | 3 | 2005 | 269 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 853 | 0.290 |
Why?
|
| Oncogenes | 2 | 2020 | 88 | 0.290 |
Why?
|
| Goiter | 2 | 2018 | 43 | 0.290 |
Why?
|
| Receptors, Notch | 3 | 2022 | 120 | 0.290 |
Why?
|
| Radiotherapy Dosage | 4 | 2020 | 468 | 0.280 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 301 | 0.280 |
Why?
|
| Thyroid Gland | 3 | 2022 | 270 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 104 | 0.280 |
Why?
|
| Patient Selection | 3 | 2020 | 685 | 0.280 |
Why?
|
| Repressor Proteins | 3 | 2015 | 403 | 0.280 |
Why?
|
| Risk Factors | 6 | 2021 | 5417 | 0.280 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 1204 | 0.270 |
Why?
|
| SEER Program | 2 | 2016 | 190 | 0.270 |
Why?
|
| Thyroid Nodule | 2 | 2016 | 51 | 0.270 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 1384 | 0.260 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 418 | 0.260 |
Why?
|
| ErbB Receptors | 2 | 2020 | 485 | 0.250 |
Why?
|
| DNA Mutational Analysis | 5 | 2016 | 526 | 0.250 |
Why?
|
| Risk Assessment | 7 | 2018 | 2261 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 2438 | 0.240 |
Why?
|
| Databases, Factual | 3 | 2018 | 814 | 0.240 |
Why?
|
| Hypothermia | 1 | 2003 | 26 | 0.230 |
Why?
|
| Quinolones | 1 | 2024 | 60 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1197 | 0.230 |
Why?
|
| Young Adult | 8 | 2022 | 5976 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 138 | 0.230 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 4 | 0.230 |
Why?
|
| Brain Neoplasms | 3 | 2015 | 763 | 0.230 |
Why?
|
| DNA, Viral | 2 | 2022 | 265 | 0.220 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 18 | 0.220 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 42 | 0.220 |
Why?
|
| Head | 1 | 2003 | 132 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 427 | 0.220 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
| Oral Health | 2 | 2022 | 10 | 0.220 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2023 | 109 | 0.210 |
Why?
|
| Decision Making | 2 | 2020 | 642 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 322 | 0.210 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 241 | 0.210 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 185 | 0.210 |
Why?
|
| Transcriptome | 3 | 2021 | 580 | 0.210 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1056 | 0.200 |
Why?
|
| Gastric Bypass | 1 | 2023 | 110 | 0.200 |
Why?
|
| Smoking | 3 | 2020 | 609 | 0.200 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 486 | 0.200 |
Why?
|
| DNA Methylation | 3 | 2015 | 628 | 0.200 |
Why?
|
| Cloud Computing | 1 | 2021 | 11 | 0.200 |
Why?
|
| DNA Helicases | 2 | 2012 | 79 | 0.200 |
Why?
|
| Societies, Medical | 4 | 2018 | 572 | 0.200 |
Why?
|
| Survival Analysis | 5 | 2018 | 1538 | 0.200 |
Why?
|
| RNA, Messenger | 4 | 2016 | 1981 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 16 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2501 | 0.190 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.190 |
Why?
|
| Parathyroidectomy | 2 | 2018 | 78 | 0.190 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 54 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 3640 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 164 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2012 | 696 | 0.190 |
Why?
|
| Larynx, Artificial | 2 | 2011 | 2 | 0.190 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 394 | 0.190 |
Why?
|
| Bacteria | 2 | 2023 | 447 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 194 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 14 | 0.180 |
Why?
|
| Oncogene Protein v-akt | 1 | 2020 | 21 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2021 | 185 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 292 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 225 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 145 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1673 | 0.180 |
Why?
|
| Cyclin D1 | 1 | 2020 | 83 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 170 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Checklist | 1 | 2020 | 57 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 219 | 0.180 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 66 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.170 |
Why?
|
| Brain Stem Neoplasms | 1 | 2019 | 17 | 0.170 |
Why?
|
| Human papillomavirus 16 | 2 | 2016 | 38 | 0.170 |
Why?
|
| Radiation Dosage | 1 | 2020 | 227 | 0.170 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.170 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 183 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
| Point Mutation | 1 | 2019 | 246 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 372 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
| Consensus | 2 | 2018 | 335 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2022 | 7993 | 0.170 |
Why?
|
| Glossectomy | 2 | 2016 | 4 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 182 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 383 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 251 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2018 | 95 | 0.160 |
Why?
|
| APOBEC Deaminases | 1 | 2017 | 5 | 0.160 |
Why?
|
| Computational Biology | 1 | 2021 | 528 | 0.160 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 379 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 262 | 0.160 |
Why?
|
| Reoperation | 3 | 2016 | 597 | 0.150 |
Why?
|
| Confidence Intervals | 1 | 2018 | 229 | 0.150 |
Why?
|
| Glottis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Metals | 1 | 2018 | 90 | 0.150 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 94 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 334 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2262 | 0.150 |
Why?
|
| Hypocalcemia | 2 | 2014 | 41 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 1686 | 0.150 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 2426 | 0.150 |
Why?
|
| Genomics | 3 | 2024 | 720 | 0.150 |
Why?
|
| Survival Rate | 3 | 2020 | 1863 | 0.150 |
Why?
|
| Adolescent | 7 | 2022 | 8981 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 165 | 0.150 |
Why?
|
| Arabinofuranosyluracil | 2 | 2007 | 6 | 0.140 |
Why?
|
| Sclerotherapy | 1 | 2016 | 16 | 0.140 |
Why?
|
| Thymidine Kinase | 2 | 2007 | 30 | 0.140 |
Why?
|
| Endoscopy | 2 | 2011 | 332 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2014 | 172 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.140 |
Why?
|
| Vascular Malformations | 1 | 2016 | 19 | 0.140 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2016 | 10 | 0.140 |
Why?
|
| Bleomycin | 1 | 2016 | 98 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2601 | 0.140 |
Why?
|
| Exons | 3 | 2015 | 450 | 0.140 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2016 | 7 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 546 | 0.140 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2015 | 34 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 31 | 0.140 |
Why?
|
| Time Factors | 5 | 2018 | 5210 | 0.140 |
Why?
|
| Receptor, Notch2 | 2 | 2012 | 6 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 3 | 2009 | 503 | 0.140 |
Why?
|
| Proton Therapy | 1 | 2015 | 27 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2016 | 84 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1208 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2018 | 328 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 479 | 0.130 |
Why?
|
| Calcium | 2 | 2018 | 1156 | 0.130 |
Why?
|
| North America | 2 | 2013 | 180 | 0.130 |
Why?
|
| China | 2 | 2014 | 228 | 0.130 |
Why?
|
| Biopsy | 1 | 2019 | 1163 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 217 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 223 | 0.130 |
Why?
|
| Spores, Bacterial | 2 | 2005 | 18 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2022 | 3241 | 0.130 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2015 | 48 | 0.130 |
Why?
|
| Carbolines | 1 | 2015 | 8 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 170 | 0.130 |
Why?
|
| Mandible | 1 | 2016 | 119 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 9 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 267 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2018 | 339 | 0.130 |
Why?
|
| Leukoplakia, Oral | 1 | 2014 | 11 | 0.130 |
Why?
|
| Algorithms | 4 | 2016 | 1830 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 160 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 67 | 0.120 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 15 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 629 | 0.120 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Gene Dosage | 2 | 2013 | 207 | 0.120 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 9 | 0.120 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 115 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 293 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2014 | 173 | 0.120 |
Why?
|
| Bacterial Toxins | 2 | 2005 | 111 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 177 | 0.120 |
Why?
|
| Age Distribution | 1 | 2014 | 204 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2016 | 195 | 0.120 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 10 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 257 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 937 | 0.120 |
Why?
|
| Metagenome | 1 | 2014 | 102 | 0.120 |
Why?
|
| Enteral Nutrition | 3 | 2020 | 102 | 0.120 |
Why?
|
| Animals | 14 | 2023 | 26582 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 37 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1075 | 0.110 |
Why?
|
| Ependymoma | 1 | 2013 | 17 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 813 | 0.110 |
Why?
|
| Mutation, Missense | 2 | 2011 | 276 | 0.110 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 38 | 0.110 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2012 | 49 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 373 | 0.110 |
Why?
|
| Receptor, Notch3 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2013 | 82 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2013 | 68 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 329 | 0.110 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 168 | 0.110 |
Why?
|
| Vocal Cords | 2 | 2011 | 25 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 56 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 81 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 51 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 180 | 0.100 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 4 | 0.100 |
Why?
|
| INDEL Mutation | 1 | 2011 | 30 | 0.100 |
Why?
|
| Geography | 1 | 2012 | 223 | 0.100 |
Why?
|
| Oligodendroglioma | 1 | 2011 | 45 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 41 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 859 | 0.100 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 64 | 0.100 |
Why?
|
| Carboplatin | 2 | 2022 | 286 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2011 | 109 | 0.100 |
Why?
|
| Child | 6 | 2022 | 6927 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2013 | 255 | 0.100 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 74 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 4 | 2005 | 1047 | 0.090 |
Why?
|
| Mice | 10 | 2021 | 11352 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2022 | 460 | 0.090 |
Why?
|
| Neurons | 3 | 2009 | 1546 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 193 | 0.090 |
Why?
|
| Models, Biological | 2 | 2015 | 1749 | 0.090 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 298 | 0.090 |
Why?
|
| Lipomatosis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Lipoma | 1 | 2010 | 25 | 0.090 |
Why?
|
| Glioma | 1 | 2012 | 285 | 0.090 |
Why?
|
| MPTP Poisoning | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cisplatin | 2 | 2022 | 612 | 0.090 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 27 | 0.090 |
Why?
|
| DNA | 1 | 2015 | 1294 | 0.090 |
Why?
|
| Intestinal Neoplasms | 1 | 2010 | 56 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 237 | 0.090 |
Why?
|
| Lung | 1 | 2015 | 1170 | 0.090 |
Why?
|
| Biomarkers | 2 | 2023 | 1718 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 689 | 0.080 |
Why?
|
| Safety Management | 2 | 2020 | 56 | 0.080 |
Why?
|
| Speech, Alaryngeal | 1 | 2008 | 3 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 94 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2016 | 93 | 0.080 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 147 | 0.080 |
Why?
|
| Voice Quality | 1 | 2008 | 11 | 0.080 |
Why?
|
| Base Sequence | 1 | 2012 | 2330 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 999 | 0.080 |
Why?
|
| Robotics | 1 | 2011 | 267 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2022 | 4213 | 0.080 |
Why?
|
| Microsurgery | 1 | 2008 | 84 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2010 | 303 | 0.080 |
Why?
|
| Oral Fistula | 1 | 2007 | 2 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1139 | 0.080 |
Why?
|
| Cutaneous Fistula | 1 | 2007 | 11 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2007 | 15 | 0.080 |
Why?
|
| Laryngoscopy | 2 | 2022 | 44 | 0.080 |
Why?
|
| Contrast Media | 1 | 2012 | 1078 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 23 | 0.080 |
Why?
|
| Longevity | 2 | 2023 | 51 | 0.070 |
Why?
|
| Muscles | 1 | 2007 | 194 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 69 | 0.070 |
Why?
|
| Rabbits | 2 | 2005 | 636 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2008 | 142 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2005 | 276 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2023 | 3612 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1805 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 744 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2007 | 265 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 674 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 182 | 0.070 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2005 | 5 | 0.070 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 5 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2022 | 290 | 0.070 |
Why?
|
| Huntington Disease | 1 | 2005 | 37 | 0.070 |
Why?
|
| Length of Stay | 3 | 2014 | 702 | 0.070 |
Why?
|
| Bacteriolysis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Behavior | 1 | 2005 | 85 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2005 | 35 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 134 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 80 | 0.060 |
Why?
|
| Bacteria, Anaerobic | 1 | 2003 | 3 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2015 | 307 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 108 | 0.060 |
Why?
|
| Histone Demethylases | 1 | 2023 | 30 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2003 | 25 | 0.060 |
Why?
|
| Microtubules | 1 | 2004 | 119 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1801 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 469 | 0.060 |
Why?
|
| Body Temperature | 1 | 2003 | 124 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2003 | 50 | 0.060 |
Why?
|
| Pharynx | 1 | 2023 | 45 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 357 | 0.060 |
Why?
|
| Adenoidectomy | 1 | 2023 | 23 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2003 | 82 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2003 | 112 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2003 | 206 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2003 | 119 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 435 | 0.050 |
Why?
|
| Clostridium Infections | 1 | 2004 | 125 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2022 | 11 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 938 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 927 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 93 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 51 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2022 | 74 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
| Apoptosis | 2 | 2005 | 1683 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 270 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 353 | 0.050 |
Why?
|
| Lip | 1 | 2021 | 16 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 223 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 263 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 162 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1186 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2020 | 24 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 148 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 556 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 1531 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 250 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 273 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 28 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 294 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 123 | 0.050 |
Why?
|
| Cell Line | 4 | 2005 | 2468 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 327 | 0.050 |
Why?
|
| Surgical Oncology | 1 | 2020 | 27 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 58 | 0.050 |
Why?
|
| Age of Onset | 1 | 2020 | 310 | 0.050 |
Why?
|
| India | 1 | 2020 | 120 | 0.050 |
Why?
|
| Deglutition | 1 | 2020 | 73 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2003 | 770 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 246 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 751 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 21 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1376 | 0.040 |
Why?
|
| Genes, myc | 1 | 2019 | 39 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1753 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 639 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 55 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 879 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
| Aging | 1 | 2023 | 691 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 252 | 0.040 |
Why?
|
| Lysine | 1 | 2019 | 147 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 260 | 0.040 |
Why?
|
| Hypoxia | 1 | 2003 | 641 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 80 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 100 | 0.040 |
Why?
|
| American Dental Association | 1 | 2017 | 9 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1196 | 0.040 |
Why?
|
| Evidence-Based Dentistry | 1 | 2017 | 10 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2005 | 3092 | 0.040 |
Why?
|
| S-Nitrosoglutathione | 2 | 2009 | 10 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2009 | 22 | 0.040 |
Why?
|
| Mouth | 1 | 2017 | 48 | 0.040 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 55 | 0.040 |
Why?
|
| N-Methylaspartate | 2 | 2009 | 51 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 183 | 0.040 |
Why?
|
| Indoles | 1 | 2019 | 318 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 62 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 311 | 0.040 |
Why?
|
| Germ Cells | 1 | 2017 | 126 | 0.040 |
Why?
|
| Exanthema | 1 | 2016 | 36 | 0.040 |
Why?
|
| Cetuximab | 1 | 2016 | 113 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 17 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 215 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2016 | 23 | 0.030 |
Why?
|
| Amines | 1 | 2016 | 27 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 35 | 0.030 |
Why?
|
| Maryland | 1 | 2015 | 35 | 0.030 |
Why?
|
| Protein Transport | 2 | 2009 | 411 | 0.030 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2015 | 37 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 42 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 74 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2015 | 42 | 0.030 |
Why?
|
| Transfection | 2 | 2009 | 896 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 413 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 83 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 15 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 121 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 81 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 348 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2016 | 69 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 2232 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 674 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 148 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 213 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 110 | 0.030 |
Why?
|
| Tadalafil | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2015 | 7 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 171 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2016 | 63 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 138 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 722 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 916 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 177 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 119 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 376 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 248 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 303 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 32 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1585 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 50 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 912 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 196 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 162 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 184 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 280 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 151 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3362 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.030 |
Why?
|
| Protein Binding | 2 | 2009 | 1456 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1578 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 425 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1991 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2005 | 790 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2012 | 3 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 280 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2009 | 1924 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2818 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 1041 | 0.030 |
Why?
|
| Baltimore | 1 | 2011 | 36 | 0.030 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 21 | 0.030 |
Why?
|
| Seroma | 1 | 2011 | 6 | 0.030 |
Why?
|
| Learning Curve | 1 | 2011 | 18 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.030 |
Why?
|
| Vocal Cord Paralysis | 1 | 2011 | 26 | 0.030 |
Why?
|
| Telomere | 1 | 2012 | 108 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 695 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 85 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 59 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2011 | 91 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 702 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 100 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2062 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 104 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 303 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 756 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 278 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 3030 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2009 | 45 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 145 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 332 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 207 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 305 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1195 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2007 | 59 | 0.020 |
Why?
|
| Visual Fields | 1 | 2008 | 98 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 943 | 0.020 |
Why?
|
| Magnetics | 1 | 2007 | 41 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 547 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 36 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 121 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 539 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2008 | 194 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 347 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 3046 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 242 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 673 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 350 | 0.020 |
Why?
|
| Densitometry | 1 | 2005 | 29 | 0.020 |
Why?
|
| Escape Reaction | 1 | 2005 | 12 | 0.020 |
Why?
|
| Electron Transport | 1 | 2005 | 71 | 0.020 |
Why?
|
| Retinal Degeneration | 1 | 2005 | 28 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 679 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 244 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 86 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 256 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 125 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 81 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 268 | 0.020 |
Why?
|
| Plasmids | 1 | 2005 | 287 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2005 | 93 | 0.020 |
Why?
|
| Cysteine | 1 | 2005 | 135 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 220 | 0.020 |
Why?
|
| Spores | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2005 | 281 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 2003 | 12 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2005 | 329 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 286 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 270 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 278 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 197 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 204 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2004 | 201 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 503 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 391 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 579 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2004 | 179 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 969 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 363 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 373 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 554 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2005 | 597 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 535 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1540 | 0.010 |
Why?
|
| Drosophila | 1 | 2005 | 498 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1135 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2216 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3990 | 0.010 |
Why?
|